Kymera Therapeutics Inc share price logo

Kymera Therapeutics Inc Share Price

NASDAQ: KYMR

Mid Cap

$87.65

+1.51

(+1.75%)

as on

Kymera Therapeutics Inc Stock Performance

as on April 18, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $87.06
    $88.45
    downward going graph

    0.67%

    Downside

    0.91%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $25.50
    $103.00
    downward going graph

    70.91%

    Downside

    17.51%

    Upside

    downward going graph

Kymera Therapeutics Inc share price movements today

Previous Close
$86.14
Open
$87.43
Volume
550.4K
Day's Low - High
$87.06 - $88.45
52 Week Low - High
$25.50 - $103.00

Kymera Therapeutics Inc Historical Returns

1 Month Return
+ 10.83 %
3 Month Return
+ 26.13 %
1 Year Return
+ 237.74 %
3 Year Return
+ 151.17 %
5 Year Return
+ 126.88 %

Kymera Therapeutics Inc Stock Fundamentals & Key Indicators

Check Kymera Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.0B

EPS (TTM)

-3.597

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-338.8M

Revenue (TTM)

39.2M

Profit Margin

0.00%

Return On Equity TTM

-25.78%

Kymera Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kymera Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$7.0B126.88%NA0.00%
BUY$41.3B122.97%133.478.45%
BUY$110.8B101.1%28.4232.94%
NA$37.2BNA131.655.37%
BUY$78.9B49.34%17.9831.41%

Stock Returns calculator for Kymera Therapeutics Inc Stock including INR - Dollar returns

The Kymera Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Kymera Therapeutics Inc investment value today

Current value as on today

₹3,65,619

Returns

₹2,65,619

(+265.62%)

Returns from Kymera Therapeutics Inc Stock

₹2,37,505 (+237.5%)

Dollar Impact

₹28,114 (+28.11%)

Analyst Recommendation on Kymera Therapeutics Inc Stock

Based on 23 analysts

BUY

69.57%

Buy

30.43%

Hold

0.00%

Sell

Based on 23 analysts, 69.57% of analysts recommend a 'BUY' rating for Kymera Therapeutics Inc. Average target price of $119.14

Kymera Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Kymera Therapeutics Inc.

What analysts predicted

26.43%UPSIDE

Target Price

$119.14

Current Price

$87.65

Analyzed by

23 Analysts

Target

$119.14

Kymera Therapeutics Inc target price $119.14, a slight upside of 26.43% compared to current price of $87.65. According to 23 analysts rating.

Kymera Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Kymera Therapeutics Inc Stock has increased by 39% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:39% versus previous 30 day period

Kymera Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
4
47
10
25
3
7
22
11
2
2
Gross Profit
4
47
10
25
3
7
22
9
-71
79
Operating Income
-57
-19
-57
-50
-72
-80
-74
-84
-92
-97
EBITDA
-51
-13
-47
-40
-60
-68
-63
-74
-79
-85
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
1
1
1
1
2
2
2
2
Income Before Tax
-52
-14
-48
-42
-62
-70
-65
-76
-82
-87
Income Tax Expense
0
4
0
-
-2
-
-
-
-
-
Net Income
-52
-14
-48
-42
-62
-70
-65
-76
-82
-87
Net Profit Margin
-1118.17%
-30.01%
-472.02%
-163.98%
-1670.33%
-956.88%
-296.75%
-667.60%
-2973.05%
-3043.01%

Kymera Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
2
34
72
46
78
47
39
Gross Profit
0
2
34
72
46
78
47
39
Operating Income
-21
-42
-46
-100
-161
-165
-261
-349
EBITDA
-21
-40
-43
-97
-151
-143
-216
-303
Interest Expense
0
0
0
0
0
0
0
0
Depreciation
0
0
1
2
2
3
7
8
Income Before Tax
-21
-41
-45
-100
-154
-146
-223
-311
Income Tax Expense
0
0
-1
-2
-2
18
-
-
Net Income
-21
-41
-45
-100
-154
-146
-223
-311
Net Profit Margin
0.00%
-1407.36%
-133.96%
-137.60%
-330.60%
-186.99%
-475.57%
-794.39%

Kymera Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-14
-48
-42
-62
-70
-65
-76
-82
-86
Operating Cash Flow
8
-39
-42
-50
-61
-79
-59
-27
-66
Investing Cash Flow
18
-330
15
-157
68
48
60
-235
-394
Financing Cash Flow
1
353
1
250
2
0
245
39
705
Change in Cash
28
-16
-25
43
9
-30
245
-222
244

Kymera Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-41
-45
-100
-154
-146
-223
-311
Operating Cash Flow
17
88
-128
-153
-102
-194
-232
Investing Cash Flow
-16
-422
-99
20
139
-404
-521
Financing Cash Flow
34
289
250
152
4
608
990
Change in Cash
36
-45
21
20
41
10
236

Global Institutional Holdings in Kymera Therapeutics Inc

Funds
Holdings
UBS Asset Mgmt Americas Inc
1.06%
venBio Select Advisor LLC
7.78%
COMMODORE CAPITAL LP
0.92%
The Goldman Sachs Group Inc
0.91%
Jennison Associates LLC
1.15%

Kymera Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 07 February

    Sun, 05:52 AM

    -

    Kymera Therapeutics' stock subject to a Lock-Up Agreement ending on 8-FEB-2026, restricting certain transactions by directors and officers.

Insights on Kymera Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, KYMR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, KYMR stock has moved up by 237.7%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, KYMR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.76M → 2.86M (in $), with an average increase of 3.4% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, -65.58M → -87.03M (in $), with an average decrease of 10.0% per quarter

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
OrganisationKymera Therapeutics Inc
Headquarters500 North Beacon Street, Watertown, MA, United States, 02472
IndustryBiotechnology
CEODr. Nello Mainolfi M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Kymera Therapeutics Inc

Name

Title

Ms. Karen Weisbach

Head of People & Culture

Mr. Bruce N. Jacobs CFA

Chief Financial Officer

Dr. Jeremy G. Chadwick Ph.D.

Chief Operating Officer

Ms. Justine E. Koenigsberg

Vice President of Investor Relations

Dr. Neil Graham M.D., M.P.H., MBBS

Chief Development Officer

Dr. Juliet Williams B.A Ph.D.

Head of Research

Dr. Bruce L. Booth DPHIL, Ph.D.

Co-Founder & Independent Chairman

Dr. Nello Mainolfi M.D., Ph.D.

Co-Founder, President, CEO & Director

Dr. Jared A. Gollob M.D.

Chief Medical Officer

Mr. Brian R. Adams J.D.

Chief Legal Officer & Corporate Secretary

FAQs

What is Kymera Therapeutics Inc share price today?

Kymera Therapeutics Inc share price today is $87.65 as on at the close of the market. Kymera Therapeutics Inc share today touched a day high of $88.45 and a low of $87.06.

What is the 52 week high and 52 week low for Kymera Therapeutics Inc share?

Kymera Therapeutics Inc share touched a 52 week high of $103 on and a 52 week low of $25.5 on . Kymera Therapeutics Inc stock price today i.e. is closed at $87.65,which is 14.90% down from its 52 week high and 243.79% up from its 52 week low.

What is Kymera Therapeutics Inc's market capitalisation today?

Kymera Therapeutics Inc market capitalisation is $0.01T as on .

How to invest in Kymera Therapeutics Inc Stock (KYMR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kymera Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kymera Therapeutics Inc Shares that will get you 0.0171 shares as per Kymera Therapeutics Inc share price of $87.65 per share as on April 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy Kymera Therapeutics Inc Stock (KYMR) from India?

Indian investors can start investing in Kymera Therapeutics Inc (KYMR) shares with as little as ₹92.575 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹925.75 in Kymera Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Kymera Therapeutics Inc share’s latest price of $87.65 as on April 18, 2026 at 1:29 am IST, you will get 0.1141 shares of Kymera Therapeutics Inc. Learn more about fractional shares .

What are the returns that Kymera Therapeutics Inc has given to Indian investors in the last 5 years?

Kymera Therapeutics Inc stock has given 126.88% share price returns and 24.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?